Fibromyalgia Trial, Recruiting NCT07361328 Sponsor: University of Utah Condition: Fibromyalgia
Back to Fibromyalgia

Fibromyalgia Trial, Recruiting

NCT07361328
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who meet the American College of Rheumatology's official criteria for fibromyalgia, which includes having widespread pain in at least 4 out of 5 body regions, pain and symptom scores above certain thresholds, and symptoms that have been present at a similar level for at least 3 months.
  • People who have tried at least two medications commonly used for fibromyalgia (such as pregabalin, duloxetine, or milnacipran) without enough benefit.
  • People who have tried at least one form of physical or movement-based therapy for fibromyalgia without enough benefit — this covers a wide range of approaches including exercise programs, water therapy, yoga, massage, stretching, heat or cold therapy, mindfulness, cognitive-behavioural therapy, and others (confirm with trial site for the full list).
  • People who rate their pain at 4 or higher out of 10 at both their screening appointment and their baseline appointment.
  • People who are willing and able to follow all study procedures, not start new treatments during the study, and stay on the same mental health treatment plan from at least one month before screening through the main study period, unless a change is recommended or agreed to by the trial doctor.
  • People who are capable of becoming pregnant must have a negative pregnancy test at screening and agree to use a highly effective form of contraception throughout the trial (such as an IUD, tubal ligation, vasectomised partner, or long-acting contraceptive).
  • People who are willing and able to give informed consent to participate.

Who may not be able to join:

  • People who have ever been diagnosed with bipolar disorder or a schizophrenia-spectrum disorder at any point in their lifetime.
  • People who have been diagnosed with a moderate or severe alcohol or other substance use disorder within the past 6 months.
  • People who have been diagnosed with obsessive compulsive disorder or post-traumatic stress disorder within the past 30 days, where that condition is considered unstable by the trial doctor.
  • People who have had a primary diagnosis of anorexia nervosa, bulimia nervosa, or binge eating disorder within the past 3 months.
  • People who have a clinically significant neurodevelopmental, neurocognitive, or personality disorder (confirm with trial site for what this may include).
  • People who are assessed as being at moderate or high risk of suicide, based on a standard screening tool called the Columbia-Suicide Severity Rating Scale, or in the judgement of the trial doctor.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Akiko Okifuji, PhD, University of Utah

Phone: 385-209-1070

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
5 January 2026
Est. completion
31 December 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Numerical Rating Scale Pain +15days. 0 (no pain) - 10 (worst pain)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov